Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer

Phase 3

Active, not recruiting

Conditions: Breast Neoplasms
HER2-positive Early Breast Cancer
Breast Cancer

Interventions: Drug: Paclitaxel
Drug: Trastuzumab Deruxtecan
Drug: Trastuzumab
Drug: Pertuzumab
Drug: Doxorubicin
Drug: cyclophosphamide

First Posted Date: 2021-11-09

Last Posted Date: 2024-11-08

Lead Sponsor: AstraZeneca

Target Recruit Count: 927

Registration Number: NCT05113251

Locations: 🇹🇭
Research Site, Khon Kaen, Thailand

Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances

Phase 1

Recruiting

Conditions: Hematological Malignancy

Interventions: Drug: Fludarabine Phosphate
Drug: Cyclophosphamide
Drug: CAR.5/IL15-transduced CB-NK cells

First Posted Date: 2021-11-08

Last Posted Date: 2024-12-12

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 48

Registration Number: NCT05110742

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer

Phase 1

Recruiting

Conditions: Glioblastoma
Primary Brain Tumor
Ependymoma
Medulloblastoma

Interventions: Drug: Ibrutinib
Drug: Indoximod
Drug: Cyclophosphamide
Drug: Etoposide

First Posted Date: 2021-11-03

Last Posted Date: 2024-07-09

Lead Sponsor: Theodore S. Johnson

Target Recruit Count: 37

Registration Number: NCT05106296

Locations: 🇺🇸
Augusta University, Georgia Cancer Center, Augusta, Georgia, United States

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

Phase 1

Recruiting

Conditions: Acute Myeloid Leukemia (AML)
B-Cell Lymphoma
Myelodysplastic Syndromes (MDS)

Interventions: Drug: CAR.70/IL15-transduced CB-NK cells
Drug: Cyclophosphamide
Drug: Fludarabine phosphate

First Posted Date: 2021-10-25

Last Posted Date: 2024-11-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 94

Registration Number: NCT05092451

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer

Phase 2

Recruiting

Conditions: Triple Negative Breast Cancer (TNBC)

Interventions: Drug: Camrelizumab
Drug: Doxorubicin
Drug: Cyclophosphamide
Drug: Docetaxel

First Posted Date: 2021-10-21

Last Posted Date: 2021-10-21

Lead Sponsor: Aiping Shi

Target Recruit Count: 30

Registration Number: NCT05088057

Locations: 🇨🇳
Aiping Shi, Changchun, Jilin, China

Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft

Phase 1

Recruiting

Conditions: Allogeneic Hematopoietic Cell Transplantation (HCT)
Advanced Hematologic Malignancies
Acute Leukemia
Chronic Myelogenous Leukemia
Myelodysplastic Syndromes
Myeloproliferative Disorders

Interventions: Drug: Purified regulatory T-cells (Treg) plus CD34+ HSPC
Drug: Fludarabine
Drug: Tacrolimus
Drug: Melphalan
Device: CliniMACS CD34 Reagent System
Drug: Plerixafor
Drug: Filgrastim granulocyte colony-stimulating factor (G-CSF) or equivalent
Drug: Thiotepa
Drug: Cyclophosphamide
Drug: Mycophenolate Mofetil (MMF)
Drug: Ruxolitinib

First Posted Date: 2021-10-21

Last Posted Date: 2024-02-20

Lead Sponsor: Stanford University

Target Recruit Count: 40

Registration Number: NCT05088356

Locations: 🇺🇸
Stanford University, Stanford, California, United States

Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma

Phase 1

Recruiting

Conditions: Recurrent High Grade B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
Refractory High Grade B-Cell Lymphoma
Refractory Transformed B-Cell Non-Hodgkin Lymphoma
HIV Infection
Recurrent Grade 3b Follicular Lymphoma
Recurrent Transformed B-Cell Non-Hodgkin Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma
Recurrent Non-Hodgkin Lymphoma
Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma

Interventions: Biological: Axicabtagene Ciloleucel
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2021-10-14

Last Posted Date: 2024-11-08

Lead Sponsor: AIDS Malignancy Consortium

Target Recruit Count: 20

Registration Number: NCT05077527

Locations: 🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Phase 1

Terminated

Conditions: Solid Tumor, Adult

Interventions: Drug: FT538
Drug: Cyclophosphamide
Drug: Fludarabine
Combination Product: Monoclonal antibody - Dose Escalation
Combination Product: Monoclonal antibody - Dose Expansion

First Posted Date: 2021-10-06

Last Posted Date: 2023-09-21

Lead Sponsor: Fate Therapeutics

Target Recruit Count: 16

Registration Number: NCT05069935

Locations: 🇺🇸
NEXT Oncology, San Antonio, Texas, United States
🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States

and more 1 locations

Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Phase 1

Recruiting

Conditions: Recurrent Diffuse Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma

Interventions: Biological: Chimeric Antigen Receptor T-Cell Therapy
Drug: Cyclophosphamide
Drug: Fludarabine Phosphate
Biological: Rituximab

First Posted Date: 2021-09-22

Last Posted Date: 2024-05-13

Lead Sponsor: Mehrdad Abedi, MD

Target Recruit Count: 36

Registration Number: NCT05052528

Locations: 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.

Phase 2

Conditions: Mature B-Cell Leukemia Burkitt Type
Burkitt Lymphoma (BL)
Unclassifiable Lymphoma Between DCBL and BL

Interventions: Drug: Rituximab
Drug: Methotrexate
Drug: Dexamethasone
Drug: Iphosphamid
Drug: Vincristine
Drug: Etoposide
Drug: Cytarabine
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vindesine
Drug: Hydrocortisone
Drug: Prednisone

First Posted Date: 2021-09-20

Last Posted Date: 2021-09-20

Lead Sponsor: PETHEMA Foundation

Target Recruit Count: 100

Registration Number: NCT05049473

Locations: 🇪🇸
Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
🇪🇸
Hospital del Mar, Barcelona, Spain
🇪🇸
ICO-Hospital Duran i Reynals, Bellvitge, Spain

and more 26 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy